Iratumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Iratumumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target CD30
Clinical data
Legal status
?
Identifiers
CAS number 640735-09-7 N
ATC code None
KEGG D04612 YesY
Chemical data
Formula C6358H9830N1682O1992S38 
Mol. mass 170 kDa
 N (what is this?)  (verify)

Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.[1]

This drug was developed by Medarex, Inc.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Iratumumab, American Medical Association.